**TARGET POPULATION**

- Neuroendocrine prostate cancer (NEPC) expression by IHC required
- Relapsed/refractory to Standard of Care (SOC)

**BASELINE CHARACTERISTICS**

- **Age (Years)**: Male 42 (59.2%)
- **Prior Therapies n (%)**: PD-L1 Inhibitors 56 (78.9%)
- **ECOG n (%)**: 1-12-24 mg QW
- **Liver**: 37 (52.1%)
- **SCLC**: 46 (64.8%)
- **Number of metastatic sites**: Median 1 (1.4%)
- **Race**: American Indian or Alaska Native 1 (1.4%)
- **Sex**: Female 29 (42.3%)

**PHARMACOKINETICS**

HPN328 exhibited linear PK, with dose-proportional increases in exposures at 0.015 to 24 mg/week.

**TIME ON TREATMENT**

- **Two DLTs were seen at priming dose of 1 mg (1.215 mg), printing dose de-escalated to 1 mg:**
  - No DLTs observed at target doses; target dose MTD not reached
- **DLIs events were most commonly with initial priming dose administration:**

**PHARMACODYNAMICS**

- **The cytokine spikes induced by target doses were lower than those induced by the priming doses:**
  - Clinical benefit in 64% (confirmed + unconfirmed) in patients with an opportunity to confirm

**ACKNOWLEDGEMENTS**

Thank you to our patients, their families, and our clinical staff who continue to make this trial possible.